SCHEMBL441276

SCHEMBL441276

Nc1cc2c(cc1N)C(=O)NC2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPOX P50336 1/20 0.46
GSK3B P49841 1/20 0.46
TDP1 Q9NUW8 4/20 0.43
CYP3A4 P08684 3/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
RGS12 O14924 2/20 0.43
BLM P54132 2/20 0.43
GNAI1 P63096 2/20 0.43
PMP22 Q01453 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CASP7 P55210 2/20 0.43
PARP1 P09874 2/20 0.43
USP2 O75604 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
CYP2C9 P11712 1/20 0.43
APEX1 P27695 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872555 0.85 GRM5 (0.43) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL3880489 0.83 PPOX (0.48) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL30991840 0.83 PPOX (0.39) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL1424404 0.83 GSK3B (0.40) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL11028071 0.83 ATAD2 (0.45) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL24414145 0.83 PPOX (0.39) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL29835162 0.83 PPOX (0.48) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL11025056 0.78 S100B (0.46) GSK3BTDP1CYP3A4MEN1KMT2A
SCHEMBL3884186 0.78 CES1 (0.37) PPOXGSK3BTDP1CYP3A4MEN1
SCHEMBL787009 0.76 TDP1 (0.50) TDP1CYP3A4MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805804-A Branched cross-linked polyamic acid solution, polyimide adhesive, and preparation method and application thereof 北京宇程科技有限公司 2022-07-29 CN claimed
US-20250205374-A1 METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE UNIVERSITY OF COPENHAGEN (DK) 2025-06-26 US disclosed
US-12281099-B2 Isoindolinone substituted indoles and derivatives as RAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-04-22 US disclosed
WO-2025051721-A1 METHOD FOR RAPID OXIDATION OF DIHYDROPYRIDAZINES TO PYRIDAZINES UNIVERSITY OF COPENHAGEN (DK) 2025-03-13 WO disclosed
EP-4520751-A1 METHOD FOR RAPID OXIDATION OF DIHYDROPYRIDAZINES TO PYRIDAZINES University of Copenhagen (DK) 2025-03-12 EP disclosed
EP-4490136-A1 METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE University of Copenhagen (DK) 2025-01-15 EP disclosed
CN-113474340-B Novel isoindolinone substituted indoles and derivatives as RAS inhibitors 勃林格殷格翰国际有限公司 2024-07-23 CN disclosed
CN-115368291-B Fluorescent probe for detecting phosgene and preparation method and use method thereof 浙江理工大学 2024-07-05 CN disclosed
CN-115368291-B Fluorescent probe for detecting phosgene and preparation method and use method thereof 浙江理工大学 2024-07-05 CN disclosed
WO-2023170174-A1 METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE UNIVERSITY OF COPENHAGEN (DK) 2023-09-14 WO disclosed
WO-2012037155-A2 TYROSINE KINASE INHIBITORS GTX, INC. (US) 2012-03-22 WO disclosed
WO-2012037155-A2 TYROSINE KINASE INHIBITORS GTX, INC. (US) 2012-03-22 WO disclosed
US-20120065233-A1 TYROSINE KINASE INHIBITORS GREGOR VLAD EDWARD (US) 2012-03-15 US disclosed
US-20120065233-A1 TYROSINE KINASE INHIBITORS GREGOR VLAD EDWARD (US) 2012-03-15 US disclosed
US-20120065233-A1 TYROSINE KINASE INHIBITORS GREGOR VLAD EDWARD (US) 2012-03-15 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20100273763-A1 ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS WOMEN & INFANTS HOSPITAL (US) 2010-10-28 US disclosed
US-20100273763-A1 ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS WOMEN & INFANTS HOSPITAL (US) 2010-10-28 US disclosed
WO-2008070557-A2 ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS WOMEN & INFANTS HOSPITAL (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273763-A1 ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS SCLY, SALL4, AS3MT PPOX 170/4885GSK3B 2903/4885TDP1 3361/4885
US-12281099-B2 Isoindolinone substituted indoles and derivatives as RAS inhibitors NRAS, KRAS, RASSF5 PPOX 2327/4885GSK3B 1993/4885TDP1 2732/4885
US-20250205374-A1 METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE ALDH3A1, SQLE, DUOX1 PPOX 46/4885GSK3B 3936/4885TDP1 2846/4885
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 PPOX 464/4885GSK3B 571/4885TDP1 3472/4885
US-20120065233-A1 TYROSINE KINASE INHIBITORS ALK, ROS1, ABL1 PPOX 3750/4885GSK3B 442/4885TDP1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.